KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Accured Expenses (2016 - 2025)

Novavax (NVAX) has 16 years of Change in Accured Expenses data on record, last reported at -$21.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 49.27% year-over-year to -$21.5 million; the TTM value through Dec 2025 reached -$322.6 million, up 16.35%, while the annual FY2025 figure was -$322.6 million, 16.35% up from the prior year.
  • Change in Accured Expenses reached -$21.5 million in Q4 2025 per NVAX's latest filing, up from -$26.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $823.0 million in Q4 2022 and bottomed at -$272.5 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $21.3 million, with a median of -$28.0 million recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 731.07% in 2021, then plummeted 316.6% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $419.6 million in 2021, then skyrocketed by 96.13% to $823.0 million in 2022, then plummeted by 103.59% to -$29.5 million in 2023, then tumbled by 43.74% to -$42.5 million in 2024, then surged by 49.27% to -$21.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$21.5 million in Q4 2025, -$26.5 million in Q3 2025, and -$62.6 million in Q2 2025.